IBT
ACAD icon

International Biotechnology Trust’s Acadia Pharmaceuticals ACAD Stock Holding History

International Biotechnology Trust’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$3.74M Buy
179,702
+28,702
+19% +$780K 1.26% 24
2023
Q2 		$3.62M Sell
151,000
-65,000
-30% -$1.44M 1.1% 29
2023
Q1 		$4.06M Buy
216,000
+116,000
+116% +$2.21M 1.13% 31
2022
Q4 		$1.59M Buy
+100,000
New +$1.56M 0.49% 40
2021
Q2 		– Sell
-59,514
Closed -$1.53M – 67
2021
Q1 		$1.53M Sell
59,514
-426,486
-88% -$18.8M 0.41% 38
2020
Q4 		$26M Hold
486,000
– – 7.1% 2
2020
Q3 		$20M Buy
486,000
+181,000
+59% +$7.82M 6.47% 4
2020
Q2 		$14.7M Sell
305,000
-32,000
-9% -$1.54M 4.89% 7
2020
Q1 		$14.2M Buy
337,000
+1,000
+0.3% +$41.2K 6.49% 5
2019
Q4 		$14.4M Buy
336,000
+268,000
+394% +$11.7M 5.18% 4
2019
Q3 		$2.45M Buy
68,000
+15,000
+28% +$455K 1.13% 21
2019
Q2 		$1.42M Sell
53,000
-216,000
-80% -$5.52M 0.52% 45
2019
Q1 		$7.22M Sell
269,000
-13,065
-5% -$305K 2.67% 13
2018
Q4 		$3.58M Buy
282,065
+217,065
+334% +$4.21M 2.22% 17
2018
Q3 		$1.03M Buy
+65,000
New +$1.02M 0.49% 43
2018
Q2 		– Sell
-42,773
Closed -$961K – 55
2018
Q1 		$961K Sell
42,773
-291,000
-87% -$8.06M 0.37% 53
2017
Q4 		$10M Buy
333,773
+93,000
+39% +$2.97M 3.54% 8
2017
Q3 		$9.07M Buy
240,773
+103,000
+75% +$3.35M 3.53% 8
2017
Q2 		$3.84M Buy
137,773
+88,122
+177% +$2.63M 1.46% 22
2017
Q1 		$1.71M Sell
49,651
-807
-2% -$28.5K 0.65% 35
2016
Q4 		$1.46M Buy
+50,458
New +$1.33M 0.66% 30

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

International Biotechnology Trust's ACAD Position: Q3 2023 in Review

International Biotechnology Trust increased its Acadia Pharmaceuticals (ACAD) stake by 19% in Q3 2023, buying an estimated $780K and bringing the position to 179,702 shares worth $3.74M. The position accounts for 1.26% of the portfolio, ranked #24.

International Biotechnology Trust first reported a position in ACAD in Q4 2016 and has held it in 21 quarters since. The position peaked at $26M in Q4 2020. 248 funds tracked by Wall St. Rank hold ACAD as of Q3 2023.

  • International Biotechnology Trust held 179,702 shares of Acadia Pharmaceuticals worth $3.74M as of Q3 2023.
  • International Biotechnology Trust bought 28,702 Acadia Pharmaceuticals shares in Q3 2023, an estimated $780K.
  • Acadia Pharmaceuticals made up 1.26% of International Biotechnology Trust's portfolio in Q3 2023, its #24 holding.
  • International Biotechnology Trust first reported a position in Acadia Pharmaceuticals in Q4 2016 and has held it in 21 quarters since.
  • International Biotechnology Trust's Acadia Pharmaceuticals position peaked at $26M in Q4 2020.
  • 248 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.